NKTR — Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. Another investigational compound, NKTR-262, a toll-like receptor agonist, is in Phase 1/2 trials for solid tumors. The company is also advancing several other drug candidates. Nektar Therapeutics maintains strategic collaboration agreements with a multitude of pharmaceutical entities, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ Global Select
- Employees: 61
- Website: https://www.nektar.com
Latest SEC filings for NKTR
- 8-K — 2026-09-08
- 10-Q — 2026-08-14
- 8-K — 2026-08-13
- 8-K — 2026-06-05
- 424B5 — 2026-05-08
- 8-K — 2026-05-08
- 10-Q — 2026-05-08
- 424B5 — 2026-05-08
- 8-K — 2026-05-07
- SCHEDULE 13G/A — 2026-05-06
Latest NKTR news
- — Can Nektar's Pipeline Progress Create Long-Term Value Amid Rivalry? (Zacks Investment Research)
- — Nektar, Protagonist, Shattuck are Leerink top picks in emerging immunology (seekingalpha_market)
- — Nektar Therapeutics: Downgrade To Hold On REZPEG Market Outlook Setback And More (seekingalpha.com)
- — Nektar drops after new mid-stage trial data for hair loss drug (seekingalpha_market)
- — Nektar Therapeutics (NKTR) Shareholder/Analyst Call Transcript (seekingalpha.com)
- — Nektar REZPEG Data Show Durable Hair Regrowth, Set Up Phase III Alopecia Trial (marketbeat.com)
- — Nektar Stock Sinks Despite Promising Hair Loss Treatment Data (barrons.com)
- — 3 Biotech Stocks Put Traders Are Targeting Today (schaeffersresearch.com)
- — New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026 (prnewswire.com)
- — Nektar Therapeutics (NASDAQ:NKTR) Stock Rated “Moderate Buy” by Sell-Side Brokerages (defenseworld.net)
Educational tool only — not investment advice.